Skip to content
  • Home
  • Services
    • Capital Raises
    • IPO
    • M&A
  • Transactions
  • The Team
    • About us
    • Contact
  • Our Approach
  • Home
  • Services
    • Capital Raises
    • IPO
    • M&A
  • Transactions
  • The Team
    • About us
    • Contact
  • Our Approach
  • EN
  • DA
  • SV
Investors

Transactions

All Transactions

We execute various transactions that vary in type, size, and structure. Explore them here.

  • Closed
  • 10. December - 2024

Prostatype Genomics

  • 9,900,000 SEK
  • Warrant Exercise
  • 10. December - 2024

Gemstone acted as financial advisor in Prostatype Genomics’ warrant exercise

Prostatype Genomics AB specializes in the development, manufacturing, and marketing of the prognostic genetic test Prostatype®. Prostatype® is a genetic test that provides a comprehensive assessment of the aggressiveness of prostate cancer.
  • Read More
  • Closed
  • 13. June - 2024

Prostatype Genomics

  • 49,500,000 SEK
  • Rights Issue
  • 13. June - 2024

Gemstone acts as financial advisor in Prostatype Genomics’ Unit Rights Issue

Prostatype Genomics AB specializes in the development, manufacturing, and marketing of the prognostic genetic test Prostatype®. Prostatype® is a genetic test that provides a comprehensive assessment of the aggressiveness of prostate cancer.
  • Read More
  • Closed
  • 7. June - 2024

Stenocare A/S

  • 5,400,000 DKK
  • Warrant Exercise
  • 7. June - 2024

Gemstone acted as financial advisor in Stenocare’s warrant exercise

Stenocare is a Danish pharmaceutical company founded in 2017. Already the following year, Stenocare became the first Danish company to obtain permits to cultivate, import, and handle medical cannabis oils in the Danish pilot Programme.
  • Read More
  • Closed
  • 5. February - 2024

Tendo AB

  • 20,200,000 SEK
  • Rights Issue
  • 5. February - 2024

Gemstone was financial advisor and sole bookrunner in Tendo’s rights issue

Tendo has developed a medical device called OneGrip that helps the user to grasp, hold and release objects. The target patient group is people with impaired hand function resulting from a spinal cord injury.
  • Read More
  • Closed
  • 12. December - 2023

Qlife Holding AB

  • 49,500,000 SEK
  • Rights Issue
  • 12. December - 2023

Gemstone acted as financial advisor in Qlife’s rights issue

Qlife has developed and patented the Egoo Health test platform, which integrates several technologies that potentially can test for a wide range of biomarkers and viruses – protein-based and molecular.
  • Read More
  • Closed
  • 31. October - 2023

Odico A/S

  • 13,800,000 DKK
  • Rights Issue
  • 31. October - 2023

Odico A/S carried out a rights issue up to 13.8 MDKK

In the past decade, Odico has pioneered multiple technologies and products aimed at digitizing and automating the construction industry. This journey of exploration and refinement has transitioned into a promising phase of commercial scale-up, driven by a new management and a strategic partnership model
  • Read More
  • Closed
  • 11. August - 2023

DecideAct A/S

  • 12,000,000 DKK
  • Rights Issue
  • 11. August - 2023

Gemstone acted as finacial advisor in DecideAct’s rights issue

DecideAct is a provider of SaaS software and solutions that move strategy execution and follow-up from manual execution to a cloud-based Strategy Execution Management platform.
  • Read More
  • Closed
  • 11. August - 2023

DecideAct A/S

  • 5,000,000 DKK
  • Debt Financing
  • 11. August - 2023

Gemstone acted as financial advisor in DecideAct’s convertible loan of 5 mDKK

DecideAct is a provider of SaaS software and solutions that move strategy execution and follow-up from manual execution to a cloud-based Strategy Execution Management platform.
  • Read More
  • Closed
  • 3. August - 2023

Qlife Holding AB

  • 4,600,000 SEK
  • Debt Financing
  • 3. August - 2023

Gemstone acted as financial advisor in Qlife’s directed issue of convertibles

Qlife has developed and patented the Egoo Health test platform, which integrates several technologies that potentially can test for a wide range of biomarkers and viruses – protein-based and molecular.
  • Read More

Rights Issue

A rights issue allows existing owners of a company priority to invest further in the company, if desired.

  • Closed
  • 13. June - 2024

Prostatype Genomics

  • 49,500,000 SEK
  • Rights Issue
  • 13. June - 2024

Gemstone acts as financial advisor in Prostatype Genomics’ Unit Rights Issue

Prostatype Genomics AB specializes in the development, manufacturing, and marketing of the prognostic genetic test Prostatype®. Prostatype® is a genetic test that provides a comprehensive assessment of the aggressiveness of prostate cancer.
  • Read More
  • Closed
  • 5. February - 2024

Tendo AB

  • 20,200,000 SEK
  • Rights Issue
  • 5. February - 2024

Gemstone was financial advisor and sole bookrunner in Tendo’s rights issue

Tendo has developed a medical device called OneGrip that helps the user to grasp, hold and release objects. The target patient group is people with impaired hand function resulting from a spinal cord injury.
  • Read More
  • Closed
  • 12. December - 2023

Qlife Holding AB

  • 49,500,000 SEK
  • Rights Issue
  • 12. December - 2023

Gemstone acted as financial advisor in Qlife’s rights issue

Qlife has developed and patented the Egoo Health test platform, which integrates several technologies that potentially can test for a wide range of biomarkers and viruses – protein-based and molecular.
  • Read More
  • Closed
  • 31. October - 2023

Odico A/S

  • 13,800,000 DKK
  • Rights Issue
  • 31. October - 2023

Odico A/S carried out a rights issue up to 13.8 MDKK

In the past decade, Odico has pioneered multiple technologies and products aimed at digitizing and automating the construction industry. This journey of exploration and refinement has transitioned into a promising phase of commercial scale-up, driven by a new management and a strategic partnership model
  • Read More
  • Closed
  • 11. August - 2023

DecideAct A/S

  • 12,000,000 DKK
  • Rights Issue
  • 11. August - 2023

Gemstone acted as finacial advisor in DecideAct’s rights issue

DecideAct is a provider of SaaS software and solutions that move strategy execution and follow-up from manual execution to a cloud-based Strategy Execution Management platform.
  • Read More
  • Closed
  • 10. July - 2023

Sound Dimension AB

  • 8,100,000 SEK
  • Rights Issue
  • 10. July - 2023

Gemstone was financial advisor in Sound Dimension’s unit rights issue

Sound Dimension AB is active in the technology sector. The company specialises in the development of technological solutions that combine audio technology and artificial intelligence.
  • Read More
  • Closed
  • 15. May - 2023

Stenocare A/S

  • 29,700,000 DKK
  • Rights Issue
  • 15. May - 2023

Gemstone acted as financial advisor in Stenocare’s Unit Rights Issue

Stenocare is a Danish pharmaceutical company founded in 2017. Already the following year, Stenocare became the first Danish company to obtain permits to cultivate, import, and handle medical cannabis oils in the Danish pilot Programme.
  • Read More
  • Closed
  • 24. April - 2023

Brain+ A/S

  • 15,700,000 DKK
  • Rights Issue
  • 24. April - 2023

Gemstone acted as financial advisor in Brain+’s unit rights issue

Brain+ is a pioneer in developing medical software to treat the cognitive symptoms of dementia, and the most common cause of dementia, namely Alzheimer’s disease.
  • Read More
  • Closed
  • 15. November - 2022

Spermosens AB

  • 24,000,000 SEK
  • Rights Issue
  • 15. November - 2022

Gemstone acted as joint financial advisor and joint bookrunner in Spermonsens’ rights issue

Spermosen’s goal is to improve male fertility diagnosis and treatment through the introduction of breakthrough products.
  • Read More

Directed Issue

In a directed issue, the existing owners’ pre-emptive right to subscribe for shares is waived, making it typically faster to implement than a rights issue.

  • Closed
  • 9. March - 2022

DecideAct A/S

  • 5,200,000 DKK
  • Directed Issue
  • 9. March - 2022

Gemstone acted as financial advisor in DecideAct’s directed issue

DecideAct is a provider of SaaS software and solutions that move strategy execution and follow-up from manual execution to a cloud-based Strategy Execution Management platform.
  • Read More
  • Closed
  • 21. March - 2019

Realfiction Holding AB

  • 7,000,000 SEK
  • Directed Issue
  • 21. March - 2019

Gemstone acted as the Danish advisor for Realfiction in their directed issue

Founded in Denmark in 2008, Realfiction is a leading innovator and provider of mixed-reality solutions and services, a market estimated to reach USD 80 billion by 2025.
  • Read More
  • Closed
  • 1. December - 2017

Stenocare A/S

  • 2,000,000 DKK
  • Directed Issue
  • 1. December - 2017

Gemstone acted as financial advisor for Stenocare in a Private Placement

Stenocare is a Danish pharmaceutical company founded in 2017. Already the following year, Stenocare became the first Danish company to obtain permits to cultivate, import, and handle medical cannabis oils in the Danish pilot Programme.
  • Read More

IPO

When preparing for a listing, a company may seek to raise capital for growth and diversify ownership among shareholders, often opting to conduct an IPO (Initial Public Offering).

  • Closed
  • 16. September - 2021

Brain+ A/S

  • 15,000,000 DKK
  • IPO
  • 16. September - 2021

Gemstone Capital acted as financial advisor for Brain+ in their IPO

Brain+ is a pioneer in developing medical software to treat the cognitive symptoms of dementia, and the most common cause of dementia, namely Alzheimer’s disease.
  • Read More
  • Closed
  • 30. August - 2021

Sound Dimension AB

  • 15,000,000 SEK
  • IPO
  • 30. August - 2021

Gemstone Capital acted as financial advisor for Sound Dimension in their IPO

Sound Dimension AB is active in the technology sector. The company specialises in the development of technological solutions that combine audio technology and artificial intelligence.
  • Read More
  • Closed
  • 22. March - 2021

Spermosens AB

  • 29,000,000 SEK
  • IPO
  • 22. March - 2021

Gemstone acted as financial advisor for Spermosens in their IPO

Spermosen’s goal is to improve male fertility diagnosis and treatment through the introduction of breakthrough products.
  • Read More
  • Closed
  • 25. November - 2020

DecideAct A/S

  • 18,500,000 DKK
  • IPO
  • 25. November - 2020

Gemstone acted financial advisor for DecideAct in their IPO

DecideAct is a provider of SaaS software and solutions that move strategy execution and follow-up from manual execution to a cloud-based Strategy Execution Management platform.
  • Read More
  • Closed
  • 21. September - 2018

Stenocare A/S

  • 18,600,000 DKK
  • IPO
  • 21. September - 2018

Gemstone acted as financial advisor in Stenocare’s IPO

Stenocare is a Danish pharmaceutical company founded in 2017. Already the following year, Stenocare became the first Danish company to obtain permits to cultivate, import, and handle medical cannabis oils in the Danish pilot Programme.
  • Read More
  • Closed
  • 12. July - 2018

Risk Intelligence A/S

  • 12,000,000 DKK
  • IPO
  • 12. July - 2018

Gemstone acted as financial advisor in Risk Intelligence’s IPO

Risk Intelligence was founded in 2001 by Hans Tino Hansen. The company has evolved into becoming a prominent company in security risk management by delivering threat and risk assessments globally.
  • Read More
  • Closed
  • 4. May - 2018

Freetrailer Group A/S

  • 14,000,000 DKK
  • IPO
  • 4. May - 2018

Gemstone acted as Financial advisor to Freetrailer in their IPO

Freetrailer has developed a digital platform that uses the Freelock electronic lock in combination with an combination with an application makes it possible to reserve, collect and return a trailer.
  • Read More
  • Closed
  • 13. July - 2017

Omnicar Holding AB

  • 14,000,000 SEK
  • IPO
  • 13. July - 2017

Gemstone was financial advisor for Omnicar in their IPO

OmniCar has developed a software solution for the car industry. The solution is developed for Citroën in Scandinavia and has been developed by OMI A/S (‘OMI’), a digital marketing agency started by OmniCar co-founder and board member Claus T. Hansen. OmniCar is a spin-off from OMI.
  • Read More
  • Closed
  • 20. June - 2017

Realfiction Holding AB

  • 21,500,000 SEK
  • IPO
  • 20. June - 2017

Gemstone was financial advisor for Realfiction in their IPO

Founded in Denmark in 2008, Realfiction is a leading innovator and provider of mixed-reality solutions and services, a market estimated to reach USD 80 billion by 2025.
  • Read More

Warrant Exercise

Companies can issue warrants, which grant investors and employees the opportunity to subscribe to new shares at a potentially favorable price later.

  • Closed
  • 10. December - 2024

Prostatype Genomics

  • 9,900,000 SEK
  • Warrant Exercise
  • 10. December - 2024

Gemstone acted as financial advisor in Prostatype Genomics’ warrant exercise

Prostatype Genomics AB specializes in the development, manufacturing, and marketing of the prognostic genetic test Prostatype®. Prostatype® is a genetic test that provides a comprehensive assessment of the aggressiveness of prostate cancer.
  • Read More
  • Closed
  • 7. June - 2024

Stenocare A/S

  • 5,400,000 DKK
  • Warrant Exercise
  • 7. June - 2024

Gemstone acted as financial advisor in Stenocare’s warrant exercise

Stenocare is a Danish pharmaceutical company founded in 2017. Already the following year, Stenocare became the first Danish company to obtain permits to cultivate, import, and handle medical cannabis oils in the Danish pilot Programme.
  • Read More

M&A

Transactions involving mergers and acquisitions (M&A), encompassing the purchase and sale of companies.

There is not any transactions within this category

Debt Financing

Capital can be raised through debt, with transactions such as convertible loans and bridge loans being common methods.

  • Closed
  • 11. August - 2023

DecideAct A/S

  • 5,000,000 DKK
  • Debt Financing
  • 11. August - 2023

Gemstone acted as financial advisor in DecideAct’s convertible loan of 5 mDKK

DecideAct is a provider of SaaS software and solutions that move strategy execution and follow-up from manual execution to a cloud-based Strategy Execution Management platform.
  • Read More
  • Closed
  • 3. August - 2023

Qlife Holding AB

  • 4,600,000 SEK
  • Debt Financing
  • 3. August - 2023

Gemstone acted as financial advisor in Qlife’s directed issue of convertibles

Qlife has developed and patented the Egoo Health test platform, which integrates several technologies that potentially can test for a wide range of biomarkers and viruses – protein-based and molecular.
  • Read More
  • Closed
  • 30. May - 2023

Sound Dimension AB

  • 1,200,000 SEK
  • Debt Financing
  • 30. May - 2023

Sound Dimension secures a bridge loan of 1.2 MSEK

Sound Dimension AB is active in the technology sector. The company specialises in the development of technological solutions that combine audio technology and artificial intelligence.
  • Read More
  • Closed
  • 15. November - 2022

Stenocare A/S

  • 11,000,000 DKK
  • Debt Financing
  • 15. November - 2022

Gemstone act as financial advisor in Stenocares establishment of a convertible loan facility

Stenocare is a Danish pharmaceutical company founded in 2017. Already the following year, Stenocare became the first Danish company to obtain permits to cultivate, import, and handle medical cannabis oils in the Danish pilot Programme.
  • Read More

Financial and strategic advisors
to high caliber growth companies
in pursuit of market leadership.

Linkedin-in
Contact
  • +45 24 24 26 00
  • info@gemstonecapital.com
  • Strandvejen 102b, 2900 Hellerup
Transactions
  • Rights Issue
  • Directed Issue
  • IPO
  • Warrant Exercise
  • M&A
  • Debt Financing
  • Rights Issue
  • Directed Issue
  • IPO
  • Warrant Exercise
  • M&A
  • Debt Financing
  • Rights Issue
  • Directed Issue
  • IPO
  • Warrant Exercise
  • M&A
  • Debt Financing
  • Rights Issue
  • Directed Issue
  • IPO
  • Warrant Exercise
  • M&A
  • Debt Financing
General
  • Our Approach
  • About us
  • Services
  • Investors
  • Privacy Policy
  • Cookie Policy
  • Our Approach
  • About us
  • Services
  • Investors
  • Privacy Policy
  • Cookie Policy
  • Our Approach
  • About us
  • Services
  • Investors
  • Privacy Policy
  • Cookie Policy
  • Our Approach
  • About us
  • Services
  • Investors
  • Privacy Policy
  • Cookie Policy

© 2025 Gemstone Capital – Designet af Aveo web&marketing

Close menu
  • Home
  • Services
    • Capital Raises
    • IPO
    • M&A
  • Transactions
  • The Team
    • About us
    • Contact
  • Our Approach
Investors
  • EN
  • DA
  • SE